Aditxt, Inc. Logo

Aditxt, Inc.

Acquires and develops biotech for autoimmunity, cancer detection, and neuro diagnostics.

ADTX | NDAQ

Overview

Corporate Details

ISIN(s):
US0070251097
LEI:
Country:
United States of America
Address:
737 N. FIFTH STREET, SUITE 200, 23219 RICHMOND
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Aditxt, Inc. is a biotechnology innovation company focused on discovering, developing, and deploying technologies to address significant health challenges. The company's business model centers on acquiring innovative and scalable life sciences companies and leveraging its business acceleration platform to drive growth and market penetration. Aditxt's portfolio includes programs targeting autoimmunity (Adimune), early cancer detection (Pearsanta), and neurological diagnostics (Adivue), with planned acquisitions in areas like reproductive health. The company aims to monetize these assets through strategic options such as mergers, sales, licenses, or IPOs to foster long-term growth.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aditxt, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aditxt, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aditxt, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.